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ABSTRACT
Objective: Prostate-specific antigen (PSA) screening
is controversial. A community jury allows presentation
of complex information and may clarify how
participants view screening after being well-informed.
We examined whether participating in a community
jury had an effect on men’s knowledge about and their
intention to participate in PSA screening.
Design: Random allocation to either a 2-day
community jury or a control group, with
preassessment, postassessment and 3-month
follow-up assessment.
Setting: Participants from the Gold Coast (Australia)
recruited via radio, newspaper and community
meetings.
Participants: Twenty-six men aged 50–70 years with
no previous diagnosis of prostate cancer.
Intervention: The control group (n=14) received
factsheets on PSA screening. Community jury
participants (n=12) received the same factsheets and
further information about screening for prostate
cancer. In addition, three experts presented information
on PSA screening: a neutral scientific advisor provided
background information, one expert emphasised the
potential benefits of screening and another expert
emphasised the potential harms. Participants
discussed information, asked questions to the experts
and deliberated on personal and policy decisions.
Main outcome and measures: Our primary
outcome was change in individual intention to have a
PSA screening test. We also assessed knowledge
about screening for prostate cancer.
Results: Analyses were conducted using intention-to-
treat. Immediately after the jury, the community jury
group had less intention-to-screen for prostate cancer
than men in the control group (effect size=−0.6 SD,
p=0.05). This was sustained at 3-month follow-up.
Community jury men also correctly identified PSA test
accuracy and considered themselves more informed
(effect size=1.2 SD, p<0.001).
Conclusions: Evidence-informed deliberation of the
harms and benefits of PSA screening effects men’s
individual choice to be screened for prostate cancer.
Community juries may be a valid method for eliciting
target group input to policy decisions.
Trial registration number: Australian and New
Zealand Clinical Trials Registry (ACTRN12612001079831).
INTRODUCTION
Screening for prostate cancer by prostate-
specific antigen (PSA) testing is controver-
sial1 and the benefits and harms of screening
are uncertain.2 The results of two large ran-
domised controlled trials of population
screening (the ERSPC trial in Europe3 and
the PLCO trial in the USA4) were much
anticipated, but the differing methods and
results have led to conflicting interpretations
Strengths and limitations of this study
▪ This is the first study to use scientific methods
to evaluate the effect of a community jury on an
individual’s knowledge and decisions.
▪ Participants in community juries make value-
based decisions from complex information and
can differentiate individual from community
choices.
▪ Expert presentations were based on large popu-
lation studies that have limitations.
▪ The sample size of this study was small, but the
results were clear and sustained.
▪ How sampling, recruitment techniques and
group processes affect community jury out-
comes are yet to be examined.
Thomas R, et al. BMJ Open 2014;4:e005691. doi:10.1136/bmjopen-2014-005691 1
Open Access Research
 o
n
 April 14, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2014-005691 on 24 December 2014. Downloaded from 
and recommendations from expert groups.5 6 Given the
uncertainty, most guidelines recommend that men
should be fully informed of the potential advantages
and disadvantages of screening prior to having a PSA
test.5 7 8 Although individuals vary in the degree to
which they want to engage themselves with the evidence
about their health concerns, a majority consistently
report an interest in sharing healthcare decisions with
their treating doctor.9 10 However, providing the
complex information relevant to men who are interested
in PSA screening remains challenging.
Citizens’ deliberation methodologies such as commu-
nity juries can facilitate the communication of complex
evidence and aim to elicit ‘informed’ community per-
spectives for the purpose of guiding services and public
policy. A range of community jury processes have been
described, but the common features are (1) participants
are drawn from the lay public; (2) the jury deliberates
on a question requiring an ethical or value-based deci-
sion (as opposed to a problem requiring a technical
solution); (3) the jury is provided with information on
the relevant issues and possible positions from expert
‘witnesses’, with the opportunity to ask them questions
and (4) the jury then engages in a deliberation phase
with participants discussing their preferences, opinions,
values and positions, and attempt to reach a consensus
position.11
Community juries have been conducted on topics
such as public health priorities,12 mammography screen-
ing13 and health research.14 15 A recent review of delib-
eration methodologies found only four unique studies
that compared deliberative methodologies with a control
group; only two of these were in relation to health
topics.11 While theoretically sound,11 community juries
are a resource-intensive process and it is uncertain
whether the views of those participating are better
‘informed’ than those of a public provided with reading
material on the same topic. It is also unclear whether
and how being informed influences a jury’s conclusions.
If community juries are to be used to inform screening
policy, it is essential to understand the capacity of a com-
munity jury process to support better-informed conclu-
sions by its participants.
The aim of this study was to examine the degree to
which participants of a community jury on PSA screening
of asymptomatic men were better ‘informed’ than other
citizens and, based on the ERSPC3 and PLCO4 trials
together with the general practice guidelines, whether
evidence-informed deliberations of the benefits and
harms of PSA screening impact on men’s intention to be
screened for prostate cancer. We conducted a rando-
mised controlled trial that compared a community jury
with men allocated to receive typical information. As part
of the community jury process, men were also asked to
deliberate on two community-focused questions:
▸ Should government campaigns be provided (on PSA
screening) and if so, what information should be
included in those campaigns?
▸ What do you, as a group of men, think about a gov-
ernment organised invitation programme for testing
for prostate cancer?
This is the first randomised controlled trial of a delib-
erative democracy process on the topic of PSA screening.
METHOD
We recruited men in the target age group of 50–70 years
from the Gold Coast region (Australia) who had no pre-
vious diagnosis of prostate cancer, using media advertise-
ments, radio interviews and community groups. Men
with a family history of prostate cancer were not
excluded from participating. Eligible and available
respondents attended a session on a Friday evening to
receive a full briefing on the study; all agreed to partici-
pate and completed a consent form, before being ran-
domly allocated to either a community jury group or a
control group (figure 1). Random allocation occurred
by each man selecting a piece of paper with the name
of either group from an opaque container. The protocol
is registered with the Australian and New Zealand
Clinical Trials Registry (ACTRN12612001079831).
All men were given standard PSA fact sheets from the
Cancer Council Australia and Andrology Australia.16 17
In addition to the factsheets, men in the community
jury group also received a Cochrane Collaboration plain
language statement,2 information from the Royal
Australian College of General Practitioners’ Guidelines
for “Preventive Activities in General Practice” pertaining
to screening for prostate cancer,7 and the Executive
Summary of ‘PSA Testing’ from the Urology Society of
Australia and New Zealand.8 Men in both groups
received $20 gift cards as reimbursement for their time
at the introductory session and for each survey. The
community jury group received an $80 gift card as reim-
bursement for attending the community jury weekend.
Men in the control group were given a follow-up survey
with a return-stamped envelope to be mailed after the
weekend.
The community jury weekend and a qualitative ana-
lysis of the jury deliberations have been described in
detail elsewhere.18 In brief, the community jury
consisted of an iterative process of education and delib-
eration. Three experts presented to the community jury
on day one: a neutral scientific advisor discussed
medical information regarding the role of the prostate,
screening tests (including PSA and digital rectal examin-
ation), explanations about changes to PSA levels, how
cancer is detected, and treatment options and potential
outcomes ( Jim Dickinson, Professor of Family Medicine,
University of Calgary). Two further experts, a urologist
and expert in prostate cancer (RG) and an expert in
evidence-based medicine (PG) presented the benefits
and harms of being screened for prostate cancer.
Although both speakers aimed to give balanced presen-
tations, one emphasised the benefits of PSA screening,
in particular selective screening (RG http://youtu.be/
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9vPt3NAcG8g) and the other the harms (PG http://
youtu.be/nifkjdZKmsU). Both presentations focused on
the evidence from the two trials of PSA population
screening. However, both presenters also made refer-
ence to lower levels of evidence relating to the risks of
metastases if a cancer remains undetected due to a lack
of screening and the consequences of treating a
localised disease detected during screening. After each
presentation, the men were able to deliberate on the
information and could ask the experts any questions.
The men reflected on the information overnight and
then returned on Sunday to deliberate and discuss the
information presented the day before, including asking
any further questions to the expert witnesses by phone.
A nominal group technique was used on both days to
elicit individual thoughts prior to group deliberations.
After the final deliberations on Sunday, including the
community-level decisions, the men in the community
jury completed the postassessment survey. Men in the
control group were contacted on Monday and either
completed the postassessment survey by phone or
mailed the survey back to researchers the same week.
Three months after the community jury weekend, all
men in both groups were recontacted and completed a
follow-up survey.
Non-protocol extension
Since they indicated a strong desire to have the experi-
ence of the community jury weekend, after their
3-month follow-up survey the control group was offered
the same community jury experience. Six of the 14 men
randomised to the control group participated in the
second community jury (figure 1). The two primary
experts were the same as for the original community
jury group; however, the scientific advisor was changed
to a female general practitioner and professor of clinical
Figure 1 Consort flow-chart of participants.
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epidemiology (JD). A final postjury survey was con-
ducted with the second community jury.
Measures
We collected demographic information, history of previ-
ous PSA testing and information sources for PSA screen-
ing at the introductory session. In each of the three
surveys, the men were asked to nominate on a scale 0–10
(0=not at all, 5=maybe and 10=absolutely), whether they
intended, while symptomless, to undergo PSA screening
for prostate cancer in the future. They were also asked to
nominate how informed they considered themselves to
be in relation to the harms and benefits of screening for
prostate cancer on a scale 0–4 (0 = not at all and 4=very).
We asked four knowledge questions in each survey that
assessed (A) the men’s knowledge about the recommen-
dation on PSA screening in the Australian general prac-
tice guidelines,7 (B) the accuracy of the PSA test and (C)
two questions about the treatment options and side
effects of prostate cancer treatment (box 1). Australia has
a primary care-based system, requiring a referral from a
general practitioner to see a urologist. General practi-
tioners are therefore responsible for the majority of the
PSA screening tests requested in Australia. For this
reason, we were interested in the participants’ knowledge
of current general practice guidelines.
Statistical analyses
Preassessment to postassessment and postassessment to
follow-up assessment differences between the groups
were examined with analysis of covariance and Fisher’s
exact test. It was anticipated that the number of PSA
tests previously undertaken would impact on a man’s
future decision to be screened for prostate cancer with
the PSA test.19 Therefore, we conducted the analyses
with adjustment for baseline intention-to-screen and the
number of times a man had already received a PSA test.
Unadjusted postassessment analyses were conducted
using an independent t test. All analyses were conducted
on an intention-to-treat basis.
RESULTS
Participant demographics
Of the 59 men who contacted the research team, 27
respondents were available on the set date and elected to
Box 1 Knowledge questions from surveys* (answers con-
sidered correct highlighted)
1 Is routine testing for prostate cancer recommended by Royal
Australian College of General Practitioners’ (RACGP)
Guidelines?
□ Yes □ No □ Do not know
2 How accurate do you think the prostate-specific antigen (PSA)
blood test is for diagnosing prostate cancer?
□Reasonably accurate but some people who do have cancer
can have a negative test result (false negative)
□Reasonably accurate but some people who do not have
cancer can have an abnormal result (false positive)
□The PSA test is not always accurate because it can have
both false-positive or false-negative results
□The PSA test is completely accurate
□Do not know
3 In terms of your knowledge about prostate cancer, could you
list some treatment options?
□ No □ Yes, please list
4 Could you list some potential side effects of treatments for
prostate cancer?
□ No □ Yes, please list
*There were originally six knowledge questions however the
answers for two (one on prevalence and the other on mortality rates
of prostate cancer) were incorrect and were deleted from analyses.
Table 1 Participant demographics
Community
jury (n=12) SD/%
Control
(n=14) SD/%
Age
Mean 61 (4.8) 62 (4.9)
Number previous PSA tests
Mean 3.9 (3.6) 2.2* (1.8)
Routine PSA testing saves lives
Frequency
Yes 7 (58%) 9 (64%)
No 2 (17%) 2 (14%)
Do not know 3 (25%) 3 (21%)
Education
Frequency
High school or less 2 (17%) 4 (28%)
Some university or TAFE 4 (33%) 4 (28%)
University/TAFE graduate 4 (33%) 1 (7%)
University postgraduate 2 (17%) 5 (36%)
*n=13 (1 missing).
PSA, prostate-specific antigen; TAFE, Technical and Further Education Institutions.
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participate in the study. One man was excluded postran-
domisation as his age exceeded the limit of the study (see
figure 1). The participating men’s ages ranged between
53 and 70 years (average 62 years, SD=4.8). Further
demographic information is described in table 1. There
was no loss to follow-up during the course of the study.
The groups were similar at baseline in age, number of
times previously screened for prostate cancer, and
whether they intended to be screened for prostate cancer
in the future. All but 3 men had previously had a PSA
test; 14 had been tested two or three times, 4 on one
occasion, 2 men six times and 3 men had been tested on
7, 8 and 12 occasions each. No men had undergone a
biopsy. At preassessment, the majority of men (16/26,
62%) agreed with the statement that routine screening
for prostate cancer saved lives, whereas 4 (15%) dis-
agreed and 6 (23%) did not know (table 1). The men
reported a variety of sources for how they had accessed
information about prostate cancer screening, with the
most common source of information being their general
practitioner (table 2).
Changes in intention-to-screen and individual knowledge
Preintervention to postintervention
At postassessment, men in the community jury group
had significantly less intention-to-screen for prostate
cancer on the 0–10 scale than men in the control group
(median score 2.5 and 7, effect size=−0.6 SD, p=0.05).
When we adjusted for baseline intention to be screened
for prostate cancer and the number of prior PSA tests,
the mean difference was 3.7 (p=0.005, table 3). The
unadjusted mean difference between the groups was 2.7
(figure 2).
After completion of the community jury weekend,
men in the jury group considered themselves more
informed about screening for prostate cancer than the
control group (median score 4 and 2, mean differ-
ence=1.7, effect size=1.2 SD, p<0.001). Compared with
the control group, the community jury group was more
likely to correctly identify that the PSA test was not
always accurate in indicating the likelihood of prostate
cancer as it had both false-positive and false-negative
results (p=0.03, table 4).
Postassessment to 3-month follow-up assessment
The influence of the community jury experience was
sustained at 3 months: men in the community jury
group maintained their intention-to-screen score at
3 months (figure 2), whereas there was a slight increase
in the control group’s future intention-to-screen for
prostate cancer. There was no further change in knowl-
edge (table 5).
Community level questions
The men in the community jury voted unanimously
(10/10) against a government campaign targeting the
public about PSA screening for prostate cancer, and
against a government organised invitation programme.
Table 2 Where do men receive information about testing
for prostate cancer
Agree Per cent
I do not look for information 3 (12)
Family and friends 11 (42)
Internet 10 (38)
Media 9 (35)
General practitioner 17 (65)
Urologist/specialist/hospital 5 (20)
N=26.
Men could endorse more than one source.
Table 3 Linear regression analysis predicting future intention-to-screen for prostate cancer
Coefficient SE β CI lower CI upper p Value
Constant −0.16 1.69 −3.66 3.35 0.93
Preassessment intention-to-screen score 0.74 0.18 0.36 1.11 0.001
Number of previous PSA tests 0.63 0.22 0.18 1.07 0.008
Group (community jury/control) −3.69 1.19 −6.16 −1.21 0.005
N=25.
These data are slightly different to Rychetnik et al’s18 analyses as they are based on intention-to-treat.
PSA, prostate-specific antigen.
Figure 2 Future intention-to-screen scores at
preassessment, postassessment, and 3-month follow-up
assessment. ○ Community jury group; Δ control group. CJ,
community jury group; M, mean score; p values based on
analysis of covariance preassessment to postassessment and
preassessment to 3-month follow-up assessment.
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Unprompted, the jury members instead suggested the
government provide a campaign that targeted general
practitioners to assist them to provide better quality and
more consistent information to their patients on the
benefits and harms of screening for prostate cancer
using the PSA test.18
Non-protocol extension
Compared with their 3-month follow-up scores, the men
from the control group who completed the second com-
munity jury also subsequently increased their self-report
score of how informed they considered themselves
(mean score increased from 2.2 to 3.7), and decreased
their future intention to be screened for prostate cancer
(mean score decreased from 8 to 2.8).
DISCUSSION
Compared with men who received standard information,
participants in a 2-day community jury considered them-
selves to be better informed about the benefits and
harms of PSA screening and reduced their stated inten-
tion to participate in screening in the future. Although
the process led to some men changing their minds
about participating in PSA screening, others said they
would continue to be tested; highlighting the individual
nature of this decision and the need for informed
consent.20
Yet, despite differences in the men’s individual inten-
tions to be screened for prostate cancer, the group was
unanimous in opposing any government-sponsored com-
munity campaigns. Our findings demonstrate the cap-
acity of a community jury to consider complex
information on the harms and benefits of screening,
and to distinguish individual from community choices.
This echoes the findings of a New Zealand community
jury on mammography screening13 which also indicated
that community juries are able to differentiate between
individual and public health needs.
All deliberative democracy methods rely on engage-
ment of those who have an interest in the topic and
agree to take part. The generalisability of our study find-
ings may be limited by the uncertain representativeness
of a jury of volunteers from the Gold Coast, Australia,
who may be different in several ways to men in the wider
Australian community. For example, 88% of our partici-
pants had already had at least one PSA test, implying
that prior to the community jury they were more likely
to be favourably disposed to PSA screening.
The authors considered PSA screening an appropriate
topic for engaging middle-aged men because the data
are equivocal and guidelines differ.2 7 8 However, we also
acknowledge the limitations of these mass population
studies. The median follow-ups of the ERSPC3 and
PLCO4 trials (13 and 11 years) are not sufficient to reli-
ably address long-term prostate cancer mortality and
their respective methodologies have been criticised.21
This limitation may have impacted the community jury
decision. Nevertheless, this pilot study does illustrate the
Table 4 Changes in men’s knowledge scores from preassessment to postassessment
Wrong to
right
Right to
right
Right to
wrong
Wrong to
wrong
n Per cent n Per cent n Per cent n Per cent p Value
Recommended by guidelines? Community jury 4 (42) 3 (25) 1 (8) 3 (25) 0.08
Control* 1 (8) 1 (8) 1 (8) 10 (77)
How accurate is the PSA test? Community jury 6 (50) 4 (33) 1 (8) 1 (8) 0.03
Control 2 (14) 9 (64) 0 (0) 3 (21)
List possible treatment options Community jury 2 (17) 7 (58) 0 (0) 2 (17) 0.6
Control 3 (21) 7 (50) 0 (0) 4 (27)
List possible side effects of treatments Community jury 3 (25) 7 (58) 0 (0) 2 (17) 0.6
Control 3 (21) 7 (50) 0 (0) 4 (27)
*n=13 (1 missing).
PSA, prostate-specific antigen.
Table 5 Changes in men’s knowledge scores postassesment to follow-up assessment
Wrong to
right Right to right
Right to
wrong
Wrong to
wrong
p Valuen Per cent n Per cent n Per cent n Per cent
Recommended by guidelines? Community jury 0 (0) 7 (58) 1 (8) 4 (33) 0.7
Control* 0 (0) 1 (7) 1 (7) 11 (85)
How accurate is the PSA test? Community jury 0 (0) 10 (83) 0 (0) 2 (17) 0.1
Control 2 (14) 9 (64) 2 (14) 1 (7)
*n=13 (1 missing).
PSA, prostate-specific antigen.
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potential of the community jury approach to instruct a
cross-section of men of different ages, with different
backgrounds and educational levels.
Whether and how the sampling and recruitment tech-
niques affect community jury outcomes are important
research questions yet to be examined. Other important
methodological questions for community research
include: what are the impacts on group decisions of nor-
mative (conformity to group thinking) or informational
(discussion of facts) influences?22 and when and how in
the deliberation process do community jury participants
form their conclusions?
Our results have implications for clinical and public
health practice. A large proportion of men have not
been engaged in an evidence-informed discussion of the
potential benefits and harms of screening prior to their
physician ordering a PSA test;23 24 have not been asked
about their screening preferences prior to a PSA screen-
ing test;25 and some doctors screen without a discus-
sion.26 Alarmingly, a study conducted in the theatre
waiting room on men waiting to undergo a transrectal
ultrasound and prostate biopsy found that 8% were
unaware of the fact that their primary care provider had
conducted a PSA screening test.27 The current practice
of PSA screening in asymptomatic men is not standar-
dised. Our findings reinforce the importance of present-
ing the potential benefits and harms of PSA testing to
men interested in being screened, primarily because
such information will lead some men to change their
mind, once fully informed. When practitioners are faced
with the difficult situation of being asked to determine
such a decision on behalf of their patient, in addition to
considering their individual patient’s history, concerns
and priorities, it may be valuable to also have available
information about community attitudes and concerns
regarding screening.20
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